Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 3/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | DDO | Q99489 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ATP4A | P20648 | 2/20 | 0.35 |
| ▸ | ATP4B | P51164 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2899660 | 0.88 | DDAH1 (0.55) | DDAH1CHEK1ALDH1A1KDM4EHTT | |
| SCHEMBL7022293 | 0.87 | CHEK1 (0.37) | DDAH1CHEK1ALDH1A1KDM4EHTT | |
| SCHEMBL6681270 | 0.83 | CHEK1 (0.45) | DDAH1CHEK1ALDH1A1KDM4EHTR6 | |
| SCHEMBL11122762 | 0.81 | CHEK1 (0.39) | DDAH1CHEK1ALDH1A1KDM4EHTR6 | |
| SCHEMBL2866147 | 0.80 | AAK1 (0.38) | CHEK1SMN1; SMN2HTR6 | |
| SCHEMBL3968950 | 0.80 | DDAH1 (0.50) | DDAH1CHEK1ALDH1A1KDM4EHTT | |
| SCHEMBL10690713 | 0.80 | GAA (0.47) | ALDH1A1HTR6 | |
| SCHEMBL8169941 | 0.80 | POLB (0.46) | — | |
| SCHEMBL4062820 | 0.79 | MGAM (0.51) | ALDH1A1TDP1 | |
| SCHEMBL28193908 | 0.79 | HTT (0.40) | DDAH1CHEK1ALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466603-A2 | Novel catechols as antimicrobial agents | Merck & Co., Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1176958-B1 | NOVEL CATECHOLS AS ANTIMICROBIAL AGENTS | MERCK & CO INC (US) | 2004-07-28 | — | — | EP | disclosed |
| EP-1417182-A1 | COMPOUNDS USEFUL FOR TREATMENT OR PREVENTION OF DISEASE MEDIATED BY ALPHA-2B-ADRENOCEPTOR | Oy Juvantia Pharma Ltd (FI) | 2004-05-12 | — | — | EP | disclosed |
| US-6545015-B2 | Useful in therapy of bacterial infections, fungal infections | MERCK & CO., INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2003008387-A1 | COMPOUNDS USEFUL FOR TREATMENT OR PREVENTION OF DISEASE MEDIATED BY ALPHA-2B-ADRENOCEPTOR | OY JUVANTIA PHARMA LTD (FI) | 2003-01-30 | — | — | WO | disclosed |
| EP-1176958-A4 | NOVEL CATECHOLS AS ANTIMICROBIAL AGENTS | MERCK & CO INC (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020040147-A1 | Useful in therapy of bacterial infections, fungal infections | HAMMOND MILTON L (US) | 2002-04-04 | — | — | US | disclosed |
| US-6348482-B1 | CONTROLLED RELEASE MICROBIOCIDES | MERCK & CO., INC. | 2002-02-19 | — | — | US | disclosed |
| EP-1176958-A1 | NOVEL CATECHOLS AS ANTIMICROBIAL AGENTS | Merck & Co., Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000066120-A1 | NOVEL CATECHOLS AS ANTIMICROBIAL AGENTS | MERCK & CO., INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040147-A1 | Useful in therapy of bacterial infections, fungal infections | HAO1, TST, ARSA | DDAH1 390/4885CHEK1 3461/4885ALDH1A1 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.